#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

CurrentView of Metastatic Cell Carcinoma of Urinary Bladder from the Standpoint of Survival in Relation to the Mode ofTherapy


Authors: R. Zachoval;  M. Urban;  J. Heráček;  M. Záleský;  J. Kuncová;  M. Lukeš
Authors‘ workplace: Urologická klinika 3. LF UK, Praha, přednosta doc. MUDr. M. Urban
Published in: Prakt. Lék. 2003; (9): 517-519
Category:

Overview

Metastatic transitional cell carcinoma of the bladder is an aggressive neoplasm characterizedby rapid growth and dissemination with median survival of typically less than 1 year. Despitethe availability of a myriad of antineoplastics with moderate-significant anti-tumor activityyielding overall response rates in the 40 % to 80 % range, randomized trials continue todemonstrate median survival rates in the 13- to 14-month range, with very limited long-termsurvival. Subsets of patients with advanced bladder cancer present additional managementproblems, including those with renal insufficiency or nontransitional-cell histology. The optimalchemotherapy combination for patients with advanced bladder cancer remains undefined,however, there is increasing recognition that in order to achieve tangible improvements incomplete response rates and survival in this disease will likely require a combination ofchemotherapy and targeted molecular therapies and in some setting adjunctive surgery.

Key words:
cell carcinoma of the bladder - chemotherapy - surgery.

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#